Invivyd announces positive LIBERTY Phase 3 topline results for VYD2311
Invivyd (IVVD) reported positive topline results from its LIBERTY Phase 3 study for VYD2311, stating safety and tolerability and that they are superior to mRNA-based COVID-19 vaccines. The company also announced plans for regulatory submissions for VYD2311.
Story updates
11:07:42 AM UTC
SquawkNews
Invivyd Announces Positive Topline Results From Liberty Phase 3 Study Demonstrating Vyd2311 Safety And Tolerability Superior To Mrna-Based Covid-19 Vaccine Announces Regulatory Submission Plans For Vyd2311